Case Name |
Date Filed |
Judge |
Drug |
Patent No(s). |
Bausch Health Ireland Ltd. v. Lupin Ltd., 19-9178 (D.N.J.) |
Apr. 1, 2019 |
Hon. Renee Marie Bumb |
Plenvu® (polyethylene glycol 3350 / sodium ascorbate / sodium sulfate / ascorbic acid / sodium chloride / potassium chloride oral solution) |
8,999,313
9,626,969
9,592,252
9,707,297
10,016,504 |
Lipocine Inc. v. Clarus Therapeutics, Inc., 19-0622 (D. Del.) |
Apr. 2, 2019 |
Hon. Leonard P. Stark |
Jatenzo® (testosterone undecanoate capsules)
Tlando™ (testerone undecanoate capusules) |
9,034,858
9,205,057
9,480,690
9,757,390
6,569,463
6,923,988 |
Bausch Health Ireland Ltd. v. Lupin Ltd., 19-0626 (D. Del.) |
Apr. 3, 2019 |
Hon. Colm F. Connolly |
Plenvu® (polyethylene glycol 3350 / sodium ascorbate / sodium sulfate / ascorbic acid / sodium chloride / potassium chloride oral solution) |
8,999,313
9,326,969
9,592,252
9,707,297
10,016,504 |
Ferring Pharms. Inc. v. Hetero USA Inc., 19-0634 (D. Del.) |
Apr. 4, 2019 |
Hon. Richard G. Andrews |
Prepopik® (citric acid / magnesium oxide / sodium picosulfate oral solution) |
8,450,338
8,481,083 |
Sun Pharm. Indus. Ltd. v. Pfizer, Inc., 19-9330 (D.N.J.) |
Apr. 5, 2019 |
Hon. Kevin McNulty |
Lyrica® CR (pregabalin extended-release tablets) |
9,393,205 |
Sun Pharm. Indus. Ltd. v. Pfizer, Inc., 19-9335 (D.N.J.) |
Apr. 5, 2019 |
Hon. Kevin McNulty |
Lyrica® CR (pregabalin extended-release tablets) |
8,945,620
9,144,559
10,022,447 |
Almirall, LLC v. Amneal Pharms. LLC, 19-0658 (D. Del.) |
Apr. 9, 2019 |
Hon. Leonard P. Stark |
Aczone® (dapsone gel) |
9,517,219 |
Silvergate Pharms., Inc. v. Amneal Pharms. LLC, 19-0678 (D. Del.) |
Apr. 11, 2019 |
Hon. Leonard P. Stark |
Epaned® (enalapril maleate oral solution) |
9,669,008
9,80,8442
10,039,745
10,154,987 |
Vanda Pharms. Inc. v. Apotex Inc., 19-0685 (D. Del.) |
Apr. 12, 2019 |
Hon. Colm F. Connolly |
Hetlioz® (tasimelteon capsules) |
10,149,829 |
Celgene Corp. v. Synthon Pharms. Inc., 19-9737 (D.N.J.) |
Apr. 12, 2019 |
Hon. Esther Salas |
Pomalyst® (pomalidomide capsules) |
10,093,647
10,093,648
10,093,649 |
Allergan Sales, LLC v. Micro Labs Ltd., 19-9759 (D.N.J.) |
Apr. 12, 2019 |
Hon. Esther Salas |
Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598
8,864937
RE43879 |
Celgene Corp. v. Sun Pharma Global FZE, 19-10099 (D.N.J.) |
Apr. 16, 2019 |
Hon. Susan D. Wigenton |
Revlimid® (lenalidomide capsules) |
7,977,357
8,193,219
8,431,598 |
Par Pharm., Inc. v. Amneal Pharms. Co. GmbH, 19-0712 (D. Del.) |
Apr. 18, 2019 |
Hon. Colm F. Connolly |
Vasostrict® (vasopressin for injection) |
9,744,209
9,750,985 |
Inspirion Delivery Sciences, LLC v. Teva Pharms. USA, Inc., 19-10464 (D.N.J.) |
Apr. 19, 2019 |
Hon. Madeline Cox Arleo |
MorphaBond® (morphine sulfate extended-release tablets) |
7,955,619 |
Bausch Health Ireland Ltd. v. Zydus Pharms. (USA), Inc., 19-10645 (D.N.J.) |
Apr. 22, 2019 |
Hon. Renee Marie Bumb |
Glumetza® (metformin HCl extended-release tablets) |
6,488,962
6,723,340
7,780,987
8,323,692 |
Cipla Ltd. v. AstraZeneca AB, 19-0733 (D. Del.) |
Apr. 24, 2019 |
Hon. Maryellen Noreika |
Nexium® (esomeprazole magnesium delayed-release oral suspension) |
6,428,810 |
Salix Pharms., Ltd. v. Sun Pharms. Indus., Ltd., 19-0734 (D. Del.) |
Apr. 24, 2019 |
Hon. Richard G. Andrews |
Xifaxan® (rifaximin tablets) |
7,045,620
7,612,199
7,902,206
7,906,542
8,158,644
8,158,781
8,835,452
8,853,231
7,915,275
8,193,196
8,518,949
8,741,904
9,271,968
7,928,115 |
Osi Pharms., LLC v. Zydus Pharms. (USA) Inc., 19-0741 (D. Del.) |
Apr. 25, 2019 |
Hon. Colm F. Connolly |
Tarceva® (erlotinib HCl tablets) |
6,900,221 |
Pfizer Inc. v. Aizant Drug Research Solutions Pvt. Ltd., 19-0743 (D. Del.) |
Apr. 25, 2019 |
Hon. Colm F. Connolly |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489
7,456,168 |
Pfizer Inc. v. Alembic Pharms., Inc., 19-0745 (D. Del.) |
Apr. 25, 2019 |
Hon. Colm F. Connolly |
Ibrance® (palbociclib capsules) |
6,936,612 |
Pfizer Inc. v. Apotex Inc., 19-0747 (D. Del.) |
Apr. 25, 2019 |
Hon. Colm F. Connolly |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489
7,456,168 |
Pfizer Inc. v. Aurobindo Pharma, Ltd., 19-0748 (D. Del.) |
Apr. 25, 2019 |
Hon. Colm F. Connolly |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489
7,456,168 |
Pfizer Inc. v. Cipla USA Inc., 19-0749 (D. Del.) |
Apr. 25, 2019 |
Hon. Colm F. Connolly |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489
7,456,168 |
Pfizer Inc. v. Dr. Reddy’s Labs., Inc., 19-0750 (D. Del.) |
Apr. 25, 2019 |
Hon. Colm F. Connolly |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489
7,456,168 |
Pfizer Inc. v. Hetero USA, Inc., 19-0751 (D. Del.) |
Apr. 25, 2019 |
Hon. Colm F. Connolly |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489
7,456,168 |
Pfizer Inc. v. Mylan Pharms. Inc., 19-0752 (D. Del.) |
Apr. 25, 2019 |
Hon. Colm F. Connolly |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489
7,456,168 |
Pfizer Inc. v. Natco Pharma, Inc., 19-0753 (D. Del.) |
Apr. 25, 2019 |
Hon. Colm F. Connolly |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489
7,456,168 |
Pfizer Inc. v. Qilu Pharma, Inc., 19-0754 (D. Del.) |
Apr. 25, 2019 |
Hon. Colm F. Connolly |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489
7,456,168 |
Pfizer Inc. v. Sun Pharm. Indus., Ltd., 19-0758 (D. Del.) |
Apr. 25, 2019 |
Hon. Colm F. Connolly |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489 |
Pfizer Inc. v. Teva Pharms. USA, Inc., 19-0759 (D. Del.) |
Apr. 25, 2019 |
Hon. Colm F. Connolly |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489
7,456,168 |
Pfizer Inc. v. Zydus Pharms. (USA) Inc., 19-0760 (D. Del.) |
Apr. 25, 2019 |
Hon. Colm F. Connolly |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489
7,456,168 |
Teijin Ltd. v. Alkem Labs. Ltd., 19-0768 (D. Del.) |
Apr. 26, 2019 |
Hon. Richard G. Andrews |
Uloric® (febuxostat tablets) |
7,361,676
8,372,872
9,107,912 |
Adamis Pharms. Corp. v. Belcher Pharms., LLC, IPR2019-01021 (PTAB) |
Apr. 26, 2019 |
N/A |
Epinephrine for injection |
9,283,197 |
Pfizer Inc. v. Aizant Drug Research Solutions Pvt. Ltd., 19-11737 (D.N.J.) |
Apr. 29, 2019 |
Hon. Renee Marie Bumb |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489
7,456,168 |
Pfizer Inc. v. Dr. Reddy’s Labs., Inc., 19-11742 (D.N.J.) |
Apr. 29, 2019 |
Hon. Renee Marie Bumb |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489
7,456,168 |
Pfizer Inc. v. Sun Pharm. Indus., Ltd., 19-11746 (D.N.J.) |
Apr. 29, 2019 |
Hon. Renee Marie Bumb |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489 |
Pfizer Inc. v. Zydus Pharms. (USA) Inc., 19-11748 (D.N.J.) |
Apr. 29, 2019 |
Hon. Renee Marie Bumb |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489
7,456,168 |
Pfizer Inc. v. Mylan Pharms. Inc., 19-0097 (N.D.W.V.) |
Apr. 29, 2019 |
Hon. Irene M. Keeley |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489
7,456,168 |
Pfizer Inc. v. Qilu Pharma, Inc., 19-1846 (E.D. Pa.) |
Apr. 29, 2019 |
Hon. Gene E.K. Pratter |
Ibrance® (palbociclib capsules) |
6,936,612
7,208,489
7,456,168 |
Arena Pharms., Inc. v. Aurobindo Pharma Ltd., 19-0811 (D. Del.) |
May 1, 2019 |
Hon. Richard G. Andrews |
Belviq® (lorcaserin HCl tablets) |
6,953,787
7,514,422
7,977,329
8,207,158
8,273,734
9,770,455 |
Bausch Health Ireland Ltd. v. Glenmark Pharms. Ltd., 19-12045 (D.N.J.) |
May 1, 2019 |
Hon. Renee Marie Bumb |
Glumetza® (metformin HCl extended-release tablets) |
6,488,962
6,723,340
7,780,987
8,323,692 |
Merck Sharp & Dohme Corp. v. Mylan Pharms. Inc., 19-0101 (N.D.W.V.) |
May 2, 2019 |
Hon. Irene M. Keeley |
Januvia® (sitagliptin phosphate tablets)
Janumet® (metformin HCI / stagliptin phosphate tablets) |
7,326,708
8,414,921 |
Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00977 (PTAB) |
May 2, 2019 |
N/A |
Lantus® Solostar (insulin glargine recombinant for injection)
Apidra® Solostar (insulin glulisine recombinant for injection)
Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution)
Toujeo® Solostar (insulin glargine recombinant subcutaneous solution)
Soliqua® (insulin glargine / lixisenatide subcanteous solution)
Admelog® Solostar (insulin lispro for injecction) |
8,603,044 |
Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00978 (PTAB) |
May 2, 2019 |
N/A |
Lantus® Solostar (insulin glargine recombinant for injection)
Apidra® Solostar (insulin glulisine recombinant for injection)
Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution)
Toujeo® Solostar (insulin glargine recombinant subcutaneous solution)
Soliqua® (insulin glargine / lixisenatide subcanteous solution)
Admelog® Solostar (insulin lispro for injecction) |
8,603,044 |
Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00979 (PTAB) |
May 2, 2019 |
N/A |
Lantus® Solostar (insulin glargine recombinant for injection)
Apidra® Solostar (insulin glulisine recombinant for injection)
Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution)
Toujeo® Solostar (insulin glargine recombinant subcutaneous solution)
Soliqua® (insulin glargine / lixisenatide subcanteous solution)
Admelog® Solostar (insulin lispro for injecction) |
8,679,069 |
Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00980 (PTAB) |
May 2, 2019 |
N/A |
Lantus® Solostar (insulin glargine recombinant for injection)
Apidra® Solostar (insulin glulisine recombinant for injection)
Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution)
Toujeo® Solostar (insulin glargine recombinant subcutaneous solution)
Soliqua® (insulin glargine / lixisenatide subcanteous solution)
Admelog® Solostar (insulin lispro for injecction) |
8,992,486 |
Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00981 (PTAB) |
May 2, 2019 |
N/A |
Lantus® Solostar (insulin glargine recombinant for injection)
Apidra® Solostar (insulin glulisine recombinant for injection)
Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution)
Toujeo® Solostar (insulin glargine recombinant subcutaneous solution)
Soliqua® (insulin glargine / lixisenatide subcanteous solution)
Admelog® Solostar (insulin lispro for injecction) |
8,992,486 |
Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00982 (PTAB) |
May 2, 2019 |
N/A |
Lantus® Solostar (insulin glargine recombinant for injection)
Apidra® Solostar (insulin glulisine recombinant for injection)
Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution)
Toujeo® Solostar (insulin glargine recombinant subcutaneous solution)
Soliqua® (insulin glargine / lixisenatide subcanteous solution)
Admelog® Solostar (insulin lispro for injecction) |
8,992,486 |
Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00987 (PTAB) |
May 2, 2019 |
N/A |
Lantus® Solostar (insulin glargine recombinant for injection)
Apidra® Solostar (insulin glulisine recombinant for injection)
Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution)
Toujeo® Solostar (insulin glargine recombinant subcutaneous solution)
Soliqua® (insulin glargine / lixisenatide subcanteous solution)
Admelog® Solostar (insulin lispro for injecction) |
9,604,008 |
Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-01022 (PTAB) |
May 2, 2019 |
N/A |
Lantus® Solostar (insulin glargine recombinant for injection)
Apidra® Solostar (insulin glulisine recombinant for injection)
Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution)
Toujeo® Solostar (insulin glargine recombinant subcutaneous solution)
Soliqua® (insulin glargine / lixisenatide subcanteous solution)
Admelog® Solostar (insulin lispro for injecction) |
9,526,844 |
Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-01023 (PTAB) |
May 2, 2019 |
N/A |
Lantus® Solostar (insulin glargine recombinant for injection)
Apidra® Solostar (insulin glulisine recombinant for injection)
Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution)
Toujeo® Solostar (insulin glargine recombinant subcutaneous solution)
Soliqua® (insulin glargine / lixisenatide subcanteous solution)
Admelog® Solostar (insulin lispro for injecction) |
9,526,844 |
Teva Pharms. USA, Inc. v. Corcept Therapeutics, Inc., PGR2019-00048 (PTAB) |
May 7, 2019 |
N/A |
Korlym® (mifepristone tablets) |
10,195,214 |
Merck Sharp & Dohme Corp. v. Torrent Pharms. Ltd., 19-0872 (D. Del.) |
May 9, 2019 |
Hon. Richard G. Andrews |
Janumet® (metformin HCl / sitagliptin phosphate tablets) |
7,326,708 |
Collegium Pharm., Inc. v. Teva Pharms. USA Inc., 19-0876 (D. Del.) |
May 9, 2019 |
Hon. Leonard P. Stark |
Xtampza® ER (oxycodone extended-release capsules) |
10,188,644 |
Bausch Health Ireland Ltd. v. Teva Pharms. USA, Inc., 19-12404 (D.N.J.) |
May 9, 2019 |
Hon. Renee Marie Bumb |
Plenvu® (polyethylene glycol 3350 / sodium ascorbate / sodium sulfate / ascorbic acid / sodium chloride / potassium chloride oral solution) |
8,999,313
9,326,969
9,292,252
9,707,297
10,016,504 |
Bayer Intellectual Property Gmbh v. Macleods Pharms. Ltd., 19-0880 (D. Del.) |
May 10, 2019 |
Hon. Timothy B. Dyk |
Xarelto® (rivaroxaban tablets) |
9,539,218 |
Hikma Pharms. USA Inc. v. Micro Labs Ltd., 19-0883 (D. Del.) |
May 10, 2019 |
Hon. Colm F. Connolly |
Mitigare® (colchicine capsules) |
8,927,607
9,399,036
9,555,029
9,675,613
9,789,108 |
Keryx Biopharms., Inc. v. Lupin Ltd., 19-0884 (D. Del.) |
May 10, 2019 |
Hon. Leonard P. Stark |
Auryxia® (ferric citrate tablets) |
5,753,706
7,767,851
8,093,423
8,299,298
8,338,642
8,609,896
8,754,257
8,754,258
8,846,976
8,901,349
9,050,316
9,387,191
9,757,416 |
Keryx Biopharms., Inc. v. Watson Labs., Inc., 19-0885 (D. Del.) |
May 10, 2019 |
Hon. Leonard P. Stark |
Auryxia® (ferric citrate tablets) |
7,767,851
8.093.423
8,299,298
8,338,642
8,609,896
8,754,257
8,754,258
8,846,976
8,901,349
9,050,316
9,328,133
9,757,416 |
Fresenius Medical Care Holdings, Inc. v. Suven Life Sciences Ltd., 19-12479 (D.N.J.) |
May 13, 2019 |
Hon. Freda L. Wolfson |
PhosLo® GelCaps (calcium acetate tablets) |
6,576,665
6,875,445 |
AstraZeneca Pharms. LP v. Aurobindo Pharma Ltd., 19-12567 (D.N.J.) |
May 15, 2019 |
Hon. Freda L. Wolfson |
Daliresp® (roflumilast tablets) |
8,536,206
8,604,064
8,618,142 |
Keryx Biopharms., Inc. v. Watson Labs., Inc., 19-0837 (D. Nev.) |
May 15, 2019 |
Hon. Richard F. Boulware, II |
Auryxia® (ferric citrate tablets) |
7,767,851
8,093,423
8,299,298
8,338,642
8,609,896
8,754,257
8,754,258
8,846,976
8,901,349
9,050,316
9,328,133
9,757,416 |
Ferring Pharms. Inc. v. Lupin Inc., 19-0913 (D. Del.) |
May 16, 2019 |
Hon. Richard G. Andrews |
Clenpiq® (sodium picosulfate / magnesium oxide / anhydrous citric acid oral solution) |
9,827,231
9,669,110 |
Kaleo, Inc. v. Adamis Pharms. Corp., 19-0917 (D. Del.) |
May 16, 2019 |
Hon. Richard G. Andrews |
Evzio® (naloxone HCl for injection) |
9,022,022
10,143,792
10,238,806 |
Keryx Biopharms., Inc. v. Par Pharm., Inc., 19-0955 (D. Del.) |
May 23, 2019 |
Hon. Leonard P. Stark |
Auryxia® (ferric citrate tablets) |
8,093,423
9,387,191 |
CyDex Pharms., Inc. v. Alembic Global Holding SA, 19-0956 (D. Del.) |
May 23, 2019 |
Hon. Leonard P. Stark |
Evomela® (melphalan HCl for injection) |
9,200,088
9,493,582 |
Valeant Pharms. North America LLC v. KVK-Tech, Inc., 19-12845 (D.N.J.) |
May 23, 2019 |
Hon. Peter G. Sheridan |
Jublia® (efinaconazole topical solution) |
10,105,444 |
Cubist Pharms. LLC v. Cipla USA, Inc., 19-12920 (D.N.J.) |
May 24, 2019 |
Hon. Brian R. Martinotti |
Cubicin RF® (daptomycin for injection) |
9,138,456 |
Keryx Biopharms., Inc. v. Par Pharm., Inc., 19-4876 (S.D.N.Y.) |
May 24, 2019 |
Hon. Edgardo Ramos |
Auryxia® (ferric citrate tablets) |
8,093,423
9,387,191 |
Actelion Pharms. Ltd. v. Natco Pharma Ltd., 19-12984 (D.N.J.) |
May 28, 2019 |
Hon. Brian R. Martinotti |
Tracleer® (bosentan tablets) |
8,309,126 |
Senju Pharm. Co., Ltd. v. Aurobindo Pharma USA Inc., 19-13348 (D.N.J.) |
June 3, 2019 |
Hon. Brian R. Martinotti |
Prolensa® (bromfenac ophthalmic solution) |
8,129,431
8,669,290
8,754,131
8,871,813
8,927,606
9,144,609
9,517,220
9,561,277
10,085,958 |
Novartis Pharms. Corp. v. Mylan Pharms. Inc., 19-1042 (D. Del.) |
June 5, 2019 |
Hon. Richard G. Andrews |
Afinitor® (everolimus tablets) |
5,665,772
8,778,962
8,436,010 |
Novartis Pharms. Corp. v. Mylan Pharms. Inc., 19-0120 (ND.W.V.) |
June 6, 2019 |
Hon. Irene M. Keeley |
Afinitor® (everolimus tablets) |
5,665,772
8,778,962
8,436,010 |
Silvergate Pharms., Inc. v. Bionpharma Inc., 19-1067 (D. Del.) |
June 7, 2019 |
Hon. Leonard P. Stark |
Epaned® (enalapril maleate oral solution) |
10,154,987 |
Mylan Pharms. Inc. v. Almirall, LLC, IPR2019-01095 (PTAB) |
June 7, 2019 |
N/A |
Aczone® (dapsone gel) |
9,517,219 |
Bausch Health Cos. Inc. v. Actavis Labs. FL, Inc., 19-13722 (D.N.J.) |
June 13, 2019 |
Hon. Stanley R. Chesler |
Relistor® (methylnaltrexone bromide tablets) |
10,307,417 |
Novartis Pharms. Corp. v. Mylan Pharms., Inc., 19-1118 (D. Del.) |
June 17, 2019 |
Hon. Leonard P. Stark |
Gilenya® (fingolimod capsules) |
9,187,405 |
Vifor (Int’l) AG v. Mylan Labs. Ltd., 19-13955 (D.N.J.) |
June 18, 2019 |
Hon. Freda L. Wolfson |
Injectafer® (ferric carboxymaltose for injection) |
7,612,109
7,754,702
8,895,612
9,376,505 |
Celgene Corp. v. Apotex Inc., 19-13994 (D.N.J.) |
June 19, 2019 |
Hon. Susan D. Wigenton |
Revlimid® (lenalidomide capsules) |
7,977,357
8,193,219
8,431,598 |
Astellas US LLC v. Dr. Reddy’s Labs., Ltd., 19-1160 (D. Del.) |
June 21, 2019 |
Hon. Colm F. Connolly |
Lexiscan® (regadenoson for injection) |
8,106,183
RE47,301
8,524,883 |
Vifor (Int’l) AG v. Mylan Labs. Ltd., 19-0126 (N.D.W.V.) |
June 20, 2019 |
Hon. Thomas S. Kleeh |
Injectafer® (ferric carboxymaltose for injection) |
7,612,109
7,754,702
8,895,612
9,376,505 |
Astellas US LLC v. Accord Healthcare, Inc., 19-1199 (D. Del.) |
June 25, 2019 |
Hon. Colm F. Connolly |
Lexiscan® (regadenoson for injection) |
8,106,183
RE47,301
8,524,883 |
Novartis Pharms. Corp. v. Mylan Pharms., Inc., 19-0128 (N.D.W.V.) |
June 25, 2019 |
Hon. Thomas S. Kleeh |
Gilenya® (fingolimod capsules) |
9,187,405 |
Pfizer Inc. v. Glenmark Pharms. Ltd., 19-1209 (D. Del.) |
June 26, 2019 |
Hon. Richard G. Andrews |
Inlyta® (axitinib tablets) |
8,791,140 |
Eisai Co. v. Alkem Labs. Ltd., 19-1213 (D. Del.) |
June 26, 2019 |
Hon. Leonard P. Stark |
Banzel® (rufinamide oral suspension) |
6,740,669 |
Eisai Co. v. Glenmark Pharms. Ltd., 19-1214 (D. Del.) |
June 26, 2019 |
Hon. Leonard P. Stark |
Banzel® (rufinamide oral suspension) |
6,740,669 |
Piramal Healthcare UK Ltd. v. Sumitomo Dainippon Pharma Co., Ltd., 19-14307 (D.N.J.) |
June 26, 2019 |
Hon. Stanley R. Chesler |
Latuda® (lurasidone HCl tablets) |
8,729,085 |
Eisai Co. v. Alkem Labs. Ltd., 19-14394 (D.N.J.) |
June 27, 2019 |
Hon. John Michael Vazquez |
Banzel® (rufinamide oral suspension) |
6,740,669 |
Bayer Intellectual Property Gmbh v. Accord Healthcare, Inc., 19-1238 (D. Del.) |
June 28, 2019 |
Hon. Timothy Belcher Dyk |
Xarelto® (rivaroxaban tablets) |
9,539,218 |
Bausch Health Ireland Ltd. v. Apotex Inc., 19-14474 (D.N.J.) |
June 28, 2019 |
Hon. Renee Marie Bumb |
Glumetza® (metformin HCl extended-release tablets) |
7,780,987
8,323,692 |
Bausch Health Ireland Ltd. v. Emcure Pharms. Ltd., 19-14480 (D.N.J.) |
June 28, 2019 |
Hon. Renee Marie Bumb |
Glumetza® (metformin HCl extended-release tablets) |
6,723,340
7,780,987
8,323,692 |
Bausch Health Ireland Ltd. v. Granules India Ltd., 19-14489 (D.N.J.) |
June 28, 2019 |
Hon. Renee Marie Bumb |
Glumetza® (metformin HCl extended-release tablets) |
6,723,340
7,780,987
8,323,692 |
Bausch Health Ireland Ltd. v. Glenmark Pharms. Ltd, 19-14502 (D.N.J.) |
June 28, 2019 |
Hon. Freda L. Wolfson |
Bryhali® (halobetasol propionate lotion) |
8,809,307 |